NEWTON, Mass. , April 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 79,800 restricted stock units (RSUs) to five newly-hired employees. These RSU awards were granted as of March 31, 2024 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan,... Read More

NEWTON, Mass. , March 6, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024 and present at the Barclays 26th Annual Global Healthcare Conference in a fireside chat on Wednesday,... Read More

NEWTON, Mass. , March 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 10,250 restricted stock units (RSUs) to two newly-hired employees. These RSU awards were granted as of February 29, 2024 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan,... Read More

Total Revenue of $146 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $112 Million for Full Year 2023, Meeting Company's Guidance Top-Line Data Readouts from Three Pivotal Phase 3 Trials Evaluating Selinexor in Endometrial Cancer, Myelofibrosis and Multiple Myeloma Expected in 2025 Company Provides Full-Year 2024 Total Revenue Guidance of $140 Million to $160 Million , Including U.S. XPOVIO Net Product Revenue... Read More

Conference Call Scheduled for Thursday, February 29, 2024 , at 8:00 a.m. ET NEWTON, Mass. , Feb. 22, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report fourth quarter and full year 2023 financial results on Thursday, February 29, 2024 . Karyopharm's management team will host a conference call and audio... Read More

NEWTON, Mass. , Feb. 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 26,850 restricted stock units (RSUs) to seven newly-hired employees. These RSU awards were granted as of January 31, 2024 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan,... Read More

Accelerating Innovation and Growth Strategy with Top-Line Data Readouts Expected in 2H 2024 and 2025 from Three Pivotal Phase 3 Studies Evaluating Selinexor in Multiple Myeloma, Endometrial Cancer and Myelofibrosis Preliminary Unaudited Full Year 2023 Total Revenue and U.S. XPOVIO ® (selinexor) Net Product Revenue Expected to be Approximately $146 Million and $112 Million , Respectively, Meeting Company's Guidance Potential... Read More

NEWTON, Mass. , Jan. 3, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the 42 nd Annual J.P. Morgan Healthcare Conference in a podium presentation on Wednesday, January 10 at 2:15 p.m. PT , followed by a question-and-answer breakout session at 2:35 p.m.... Read More

NEWTON, Mass. , Jan. 2, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted 42,000 restricted stock units (RSUs) to one newly-hired employee. This RSU award was granted as of December 31, 2023 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as an... Read More

Biomarker Data from Phase 1 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis (MF) Suggestive of Disease Modification Data Reinforce the Potential for Selinexor in Combination with Ruxolitinib to Become a Novel, First-Line Treatment for JAKi-Naïve Patients with MF NEWTON, Mass. , Dec. 10, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical... Read More

NEWTON, Mass. , Dec. 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 15,700 restricted stock units (RSUs) to three newly-hired employees. These RSU awards were granted as of November 30, 2023 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive... Read More

NEWTON, Mass. , Nov. 8, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the following investor conferences in November: Jefferies 2023 London Healthcare Conference Format: Fireside chat Date: Wednesday, November 15, 2023 Time: 8:00 a.m. ET / 1:00 p.m. GMT... Read More

Long-Term Safety and Efficacy Data from SIENDO Study in the TP53 Wild-Type Exploratory Subgroup Showed Signals of Improvement in Overall Survival (OS) Regardless of Mismatched Repair Status (MMR) Median OS Not Reached for Selinexor-Treated Patients Who are TP53 Wild-Type pMMR NEWTON, Mass. , Nov. 6, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel... Read More

Long-Term Selinexor Data in Myelofibrosis will be Presented as Part of Oral Presentation NEWTON, Mass. , Nov. 2, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that several abstracts that include selinexor data in myelofibrosis (MF) have been selected for presentation at the 65th American Society of Hematology... Read More

Achieved Third Quarter 2023 Total Revenue of $36.0 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $30.2 Million Maintains Full Year 2023 Total Revenue Guidance of $145 Million to $160 Million , Including U.S. XPOVIO Net Product Revenue Guidance of $110 Million to $125 Million Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis... Read More

Phase 1b /2 Trial Will Investigate Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma Progressing after T-cell Immunotherapies Expected to be Initiated 1H 2024 NEWTON, Mass. , Oct. 30, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has entered into a clinical... Read More

Conference Call Scheduled for Thursday, November 2, 2023 , at 8:00 a.m. ET NEWTON, Mass. , Oct. 26, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report third quarter 2023 financial results on Thursday, November 2, 2023 . Karyopharm's management team will host a conference call and audio webcast at 8:00... Read More

NEWTON, Mass. , Oct. 2, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 83,850 restricted stock units (RSUs) to four newly-hired employees. These RSU awards were granted as of September 30, 2023 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive... Read More

NEWTON, Mass. , Sept. 26, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that several abstracts detailing new selinexor data have been selected to be presented at the 2023 International Myeloma Society (IMS) Annual Meeting, being held September 27-30 in Athens, Greece . In addition, exploratory subgroup analyses... Read More

NEWTON, Mass. , Sept. 5, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the following investor conferences in September: H.C. Wainwright 25th Annual Global Investment Conference Format: Podium presentation Date: Monday, September 11, 2023 Time: 12:30... Read More

NEWTON, Mass. , Sept. 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 58,850 restricted stock units (RSUs) to six newly-hired employees. These RSU awards were granted as of August 31, 2023 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan,... Read More

NEWTON, Mass. , Sept. 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Zhen Su , MD, MBA, to its Board of Directors, effective August 31, 2023 . Dr. Su is currently Chief Executive Officer and a member of the Board of Directors at Marengo Therapeutics, Inc., a company pioneering novel T-cell... Read More

Achieved Second Quarter 2023 Total Revenue of $37.6 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $28.5 Million Maintains Full Year 2023 Total Revenue Guidance of $145 Million to $160 Million , Including U.S. XPOVIO Net Product Revenue Guidance of $110 Million to $125 Million Announces ~20% Workforce Reduction Enhancing Financial Strength; Further Reduces Full Year 2023 Non-GAAP R&D and SG&A Expense Guidance to... Read More

NEWTON, Mass. , Aug. 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 26,350 restricted stock units (RSUs) to 4 newly-hired employees. These RSU awards were granted as of July 31, 2023 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as... Read More

Conference Call Scheduled for Wednesday, August 2, 2023 , at 8:00 a.m. ET NEWTON, Mass. , July 26, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report second quarter 2023 financial results on Wednesday, August 2, 2023 . Karyopharm's management team will host a conference call and audio webcast at 8:00... Read More

Signal of PFS Improvement in SIENDO for Selinexor-Treated Patients was Observed Only in Subgroup Who are TP53 Wild-Type with a Median Progression-Free Survival of 27.4 Months Median PFS Not Reached for Selinexor-Treated Patients Who are TP53 Wild-Type MSS (pMMR) Updated Analysis Provides Further Rationale for XPORT-EC-042, the Ongoing Pivotal Phase 3 Study (NCT05611931) Evaluating Selinexor as Maintenance Therapy in TP53... Read More

Data Provide Further Support for Company's Ongoing Phase 3 Study Evaluating Selinexor as Maintenance Therapy Following Systemic Therapy in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer NEWTON, Mass. , July 19, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that an updated exploratory... Read More

Regulatory Designation Includes Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis and Post-Polycythemia Vera Myelofibrosis Pivotal Phase 3 Study of Selinexor and Ruxolitinib in Treatment-Naïve Myelofibrosis Initiated in June 2023 NEWTON, Mass. , July 17, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today... Read More

NEWTON, Mass. , July 5, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 171,400 restricted stock units (RSUs) to 11 newly-hired employees. These RSU awards were granted as of June 30, 2023 pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as... Read More

Phase 3 Study is Supported by Previously Presented Phase 1 Study Results, Including a 78.6% SVR35 and 58.3% TSS50 in Intent to Treat Patients at Week 24 at the 60mg Dose NEWTON, Mass. , June 28, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the initiation of a pivotal Phase 3 clinical trial (XPORT-MF-034)... Read More

NEWTON, Mass. , June 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 44,600 restricted stock units (RSUs) to eight newly-hired employees. These RSU awards were granted as of May 31, 2023 pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as... Read More

NEWTON, Mass. , June 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the Jefferies Healthcare Conference in a fireside chat on Thursday, June 8, 2023 at 10:00 a.m. ET in New York, NY . A live webcast of the fireside chat can be accessed under "Events &... Read More

NEWTON, Mass. , May 23, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that several abstracts detailing new selinexor data have been selected to be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 2-6 in Chicago, Illinois and the 2023 European Hematology Association... Read More

Achieved First Quarter 2023 Total Revenues of $38.7 Million , including XPOVIO® (selinexor) Net Product Revenue of $28.3 Million , Adversely Impacted by Increased Utilization of Patient Assistant Programs (PAP) and Higher Gross to Net; YoY Growth in Total Demand 1 Rapid, Deep and Sustained Spleen and Symptom Responses Observed in the Phase 1 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis;... Read More

Relapsed/Refractory MDS Patients Achieved Median Overall Survival of 8.7 months Historically, Median Overall Survival in this Hard to Treat Patient Population is Only 4-6 Months 1,2 Results Indicate Potential Single Agent Activity of Eltanexor in Patients with R/R MDS NEWTON, Mass. , May 3, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer... Read More

NEWTON, Mass. , May 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 10,600 restricted stock units (RSUs) to four newly-hired employees, with a grant date of April 30, 2023 . Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award... Read More

Conference Call Scheduled for Thursday, May 4, 2023 , at 8:00 a.m. ET NEWTON, Mass. , May 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report first quarter 2023 financial results on Thursday, May 4, 2023 . Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on... Read More

At Week 24, 60mg of Selinexor in Combination with Ruxolitinib Achieved: 92% SVR35 and 78% TSS50 in Efficacy Evaluable Population, 79% SVR35 and 58% TSS50 in Intent to Treat Population Rapid, Deep, Sustained Spleen Response Across all Subgroups, Robust Symptom Improvement with a Generally Tolerable and Manageable Side Effect Profile; 60mg Selinexor is the Recommended Dose in Combination with Ruxolitinib Planning to Initiate... Read More

Updated Safety and Efficacy Data Will be Presented in a Poster Session at AACR 2023 from All Patients Enrolled in the Phase 1 Study Company to Host Investor Webcast Featuring a Key Opinion Leader on April 18, 2023 at 4:30 p.m. ET to Discuss Updated Results NEWTON, Mass. , April 14, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies,... Read More

NEWTON, Mass. , April 3, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 221,900 restricted stock units (RSUs) to thirteen newly-hired employees. These RSU awards were granted as of March 31, 2023 . Each RSU award will vest over three years, with 33 1/3% percent of the shares... Read More

NEWTON, Mass. , March 14, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that results from its Phase 1 study evaluating the safety and efficacy of once-weekly selinexor in combination with standard dose ruxolitinib in patients with treatment-naïve myelofibrosis (NCT04562389) have been selected for a poster... Read More

NEWTON, Mass. , March 8, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the Barclays Global Healthcare Conference in a fireside chat on Wednesday, March 15 at 4:35 p.m. ET. A live webcast of the fireside chat, along with accompanying slides, can be... Read More

NEWTON, Mass. , March 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 111,250 restricted stock units (RSUs) to eight newly-hired employees. These RSU awards were granted as of February 28, 2023 pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as... Read More

Based on Results from Phase 3 BOSTON Study, Marketing Authorization Expands Multiple Myeloma Indication NEWTON, Mass. and FLORENCE, Italy , Feb. 21, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group ("Menarini"), a privately-held, leading international pharmaceutical company, today announced that the United... Read More

Total Revenue of $157.1 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $120.4 Million for Full Year 2022, Meeting Company's Guidance Updated Results from the Phase 1 Study of Selinexor in Combination with Ruxolitinib in Patients with Treatment-Naïve Myelofibrosis and Interim Data from the Phase 2 Study Evaluating Eltanexor in Relapsed/Refractory Myelodysplastic Neoplasms Expected in 1H 2023 Company Provides Full... Read More

NEWTON, Mass. , Feb. 9, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the virtual SVB Securities Global Biopharma Conference in a fireside chat on Thursday, February 16 at 11:20 a.m. ET . A live webcast of the fireside chat, along with accompanying... Read More

Conference Call Scheduled for Wednesday, February 15, 2023 , at 8:00 a.m. ET NEWTON, Mass. , Feb. 8, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report fourth quarter and full year 2022 financial results on Wednesday, February 15, 2023 . Karyopharm's management team will host a conference call and audio... Read More

NEWTON, Mass. , Feb. 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. ( Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 113,250 restricted stock units (RSUs) to ten newly-hired employees. These RSU awards were granted as of January 31, 2023 pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as... Read More

Preliminary Unaudited Full Year 2022 Total Revenue and U.S. XPOVIO ® (selinexor) Net Product Revenue Expected to be Approximately $157.7 Million and $120.4 Million , Respectively, Meeting Company's Guidance Initiated Pivotal Phase 3 Study Evaluating Selinexor as a Maintenance Therapy in Women with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer; Encouraging Updated Exploratory Subgroup Analysis in Patients with TP53... Read More

NEWTON, Mass. , Jan. 4, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the 41 st Annual J.P. Morgan Healthcare Conference in a podium presentation on Wednesday, January 11 at 10:30 a.m. PT , followed by a question-and-answer breakout session at 10:50... Read More

NEWTON, Mass. , Jan. 3, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted stock options to purchase an aggregate of 24,300 shares of Karyopharm's common stock and an aggregate of 16,600 restricted stock units (RSUs) to four newly-hired employees. These equity awards were granted as of December... Read More

A 92% SVR35 and a 67% TSS50 were Observed in the Efficacy Evaluable Patients at Week 24 57% of Transfusion Independent Patients Achieved Hemoglobin Stabilization Company to Host Investor and Analyst Webcast Featuring Key Opinion Leaders Today at 8:30 a.m. ET NEWTON, Mass. , Dec. 12, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies,... Read More

Key Opinion Leaders to Review Highlights from Updated Phase 1 Data to be Presented at ASH 2022 at Company Sponsored Event on Monday, December 12 at 8:30 AM ET NEWTON, Mass. , Dec. 5, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will host a webcast to discuss the updated results from the Phase 1 open-label,... Read More

NEWTON, Mass. , Dec. 5, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has entered into a securities purchase agreement with certain institutional investors for a private placement that is expected to result in gross proceeds of approximately $165 million before deducting any offering related expenses. The... Read More

NEWTON, Mass. , Dec. 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted stock options to purchase an aggregate of 6,100 shares of Karyopharm's common stock and an aggregate of 4,200 restricted stock units (RSUs) to two newly-hired employees. These equity awards were granted as of November... Read More